» Articles » PMID: 16788217

Helicobacter Pylori Antibiotic Resistance in a Dutch Region: Trends over Time

Overview
Journal Neth J Med
Specialty General Medicine
Date 2006 Jun 22
PMID 16788217
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Aim: Most patients treated for H. pylori infection receive empirical therapy based on epidemiological data of antibiotic resistance. However, previous European studies indicate that resistance patterns may be changing. Therefore, the aim of this study was to investigate the prevalence of primary clarithromycin and/or metronidazole resistant H. pylori strains over a six-year period (1997-2002) in a regional hospital.

Methods: All patients visiting Slingeland Hospital in Doetinchem, the Netherlands between 1997 and 2002 with a positive H. pylori culture were included in this study. Susceptibility to metronidazole and clarithromycin was determined by disk diffusion.

Results: Of the 1355 patients with an H. pylori positive culture, 1127 did not have a history of H. pylori eradication, 58 did, and for 170 this information was not available. Mean rates of primary resistance to metronidazole and clarithromycin were 14.4% (162/1125) and 1.0% (11/1123), respectively. Primary metronidazole resistance was stable throughout the study period and primary clarithromycin resistance showed a decreasing trend. Patients of foreign descent and from secondary care had a higher chance of harbouring primary metronidazole-resistant H. pylori (adjusted OR (95% CI) 1.75 (1.1 to 2.8), and 1.60 (1.1 to 2.2), respectively). Patients with failed H. pylori eradication had a higher chance of harbouring metronidazole-resistant H. pylori (43 vs 14%, p<0.0001) and clarithromycin-resistantH. pylori (5.3 vs 1.0%, p=0.004) than untreated patients.

Conclusion: Primary metronidazole resistance is stableat a low level, while primary clarithromycin resistance isvirtually absent in the eastern part of the Netherlands.Therefore, triple therapy with a proton pump inhibitor,clarithromycin and amoxicillin can remain the empiricaltreatment of choice in the Netherlands.

Citing Articles

Antibacterial resistance and the success of tailored triple therapy in Helicobacter pylori strains isolated from Slovenian children.

Butenko T, Jeverica S, Orel R, Homan M Helicobacter. 2017; 22(5).

PMID: 28653787 PMC: 5637919. DOI: 10.1111/hel.12400.


Trends in secondary antibiotic resistance of Helicobacter pylori from 2007 to 2014: has the tide turned?.

Boltin D, Ben-Zvi H, Perets T, Kamenetsky Z, Samra Z, Dickman R J Clin Microbiol. 2014; 53(2):522-7.

PMID: 25428158 PMC: 4298548. DOI: 10.1128/JCM.03001-14.


Recent Insights into Antibiotic Resistance in Helicobacter pylori Eradication.

Wu W, Yang Y, Sun G Gastroenterol Res Pract. 2012; 2012:723183.

PMID: 22829809 PMC: 3398622. DOI: 10.1155/2012/723183.


Multicenter survey of routine determinations of resistance of Helicobacter pylori to antimicrobials over the last 20 years (1990 to 2009) in Belgium.

Miendje Deyi V, Bontems P, Vanderpas J, De Koster E, Ntounda R, Van den Borre C J Clin Microbiol. 2011; 49(6):2200-9.

PMID: 21450969 PMC: 3122765. DOI: 10.1128/JCM.02642-10.


Efficacy of serology driven "test and treat strategy" for eradication of H. pylori in patients with rheumatic disease in the Netherlands.

De Leest H, Steen K, Lems W, Van de Laar M, Huisman A, Kadir S Eur J Clin Microbiol Infect Dis. 2011; 30(7):903-8.

PMID: 21293900 PMC: 3104134. DOI: 10.1007/s10096-011-1174-5.